Document Detail

Efficacy of maternal serum screening in the prenatal detection of fetal chromosome abnormalities in Japanese women.
MedLine Citation:
PMID:  10720877     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: This prospective study assesses the efficacy of maternal serum screening for use in prenatal diagnosis of fetal anomaly and chromosome imbalance in Japanese women. METHODS: Maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol were measured in 1,055 singleton pregnant women between 14 and 20 weeks of gestation. A calculated risk for trisomy 21 of >/=1/299 or alpha-fetoprotein >/=2.5 multiples of the median was adopted as positive. RESULTS: Three hundred and seventy-eight of the 1, 055 women screened (35.8%) were identified as positive. Sensitivity, false-positive rate, and positive predictive value in women aged <35 years were 60.0, 10.6, and 6.8%, respectively, and these values were 87.5, 49.3, and 4.2%, respectively, in women aged >/=35 years. The false-positive rate in women aged <35 years was significantly lower than that for women aged >/=35 years (p < 0.001). Chromosomal abnormalities were identified in 21 cases, including 10 with trisomy 21, 5 with trisomy 18, 2 with trisomy 13, and 4 with other chromosomal disorders. Seventeen of the 21 cases (81.0%) showed screen-positive results, and among these all 10 cases with trisomy 21 were detectable. Two cases with trisomy 18, 1 with trisomy 13 and 1 with isochromosome X showed extremely low human chorionic gonadotropin levels (0.4 +/- 0.1 multiples of the median, mean +/- SE), although they were screen negative. Of the 264 women who did not undergo amniocentesis, none had any clinical findings consistent with aneuploidy after birth. CONCLUSIONS: Our results suggest that the evaluation of each serum marker, as well as of the calculated risk, was significantly important in the prenatal detection of fetal aneuploidy.
T Kishida; N Hoshi; R Hattori; H Negishi; H Yamada; K Okuyama; K Hanatani; T Takagi; T Sagawa; S Fujimoto
Related Documents :
20466537 - Impact of information about risks and benefits of cancer screening on intended particip...
1627717 - Ineffective recruitment strategies for screening mammography: letterbox drops and invit...
17510087 - Identifying people at risk for undiagnosed type 2 diabetes using the gp's electronic me...
16152577 - Increase in skin cancer screening during a community-based randomized intervention trial.
18299277 - Occupational exposure to pesticides and risk of adult brain tumors.
18407347 - A weight-of-evidence approach to assessing the ecological impact of organotin pollution...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Fetal diagnosis and therapy     Volume:  15     ISSN:  1015-3837     ISO Abbreviation:  Fetal. Diagn. Ther.     Publication Date:    2000 Mar-Apr
Date Detail:
Created Date:  2000-05-05     Completed Date:  2000-05-05     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9107463     Medline TA:  Fetal Diagn Ther     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  112-7     Citation Subset:  IM    
Copyright Information:
Copyright 2000 S. Karger AG, Basel.
Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Sapporo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chorionic Gonadotropin / blood*
Chromosome Aberrations*
Chromosomes, Human, Pair 13
Chromosomes, Human, Pair 18
Down Syndrome / diagnosis
Estriol / blood*
False Positive Reactions
Gestational Age
Maternal Age
Pregnancy, High-Risk
Prenatal Diagnosis / methods*
Prospective Studies
Sensitivity and Specificity
alpha-Fetoproteins / analysis*
Reg. No./Substance:
0/Chorionic Gonadotropin; 0/alpha-Fetoproteins; 50-27-1/Estriol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Maternal serum screening for down syndrome by using alpha-fetoprotein and human chorionic gonadotrop...
Next Document:  Maternal contamination at fetal muscle biopsy.